USD10
AARD Shares
About Aardvark TherapeuticsAardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

USD10
AARD Shares
About Aardvark TherapeuticsAardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Stats

TRADING WINDOW

Closed

OPENS AT

Not enough data

MARKET CAP

$128.24M

OPEN PRICE

$6.21

LOW (1Y)

$3.35

HIGH (1Y)

$17.94

LOW (24H)

$5.76

HIGH (24H)

$6.21

VOLUME (24H)

$218.46K

48.84%

Price history

Time
Price
Change
Today
$6.21
5.64%
1 Day
$6.27
6.52%
1 Week
$7.29
19.62%
1 Month
$3.88
51.03%
1 Year
$12.00
51.17%
Past performance is not a reliable indicator of future results.

Discover more

Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.